| Objective: To observe the changes of serum apolipoprotein A1 (ApoA1), human insulin-like growth factor-1 (IGF-1), monocyte chemoattractant protein-1 (MCP-1) and vascular endothelial function in elderly patients with unstable angina pectoris (UAP) after combined treatment with tirofiban and Naoxintong capsule. Methods: Random number table method was used, 150 elderly UAP patients admitted to our hospital from January 2020 to December 2022 were divided into control group (tirofiban treatment, n=75) and observation group (Naoxintong capsule combined with tirofiban treatment, n=75). The efficacy, clinical symptoms, cardiac function indexes, vascular endothelial function indexes and serum ApoA1, IGF-1 and MCP-1 levels were compared between two groups. Results: The total number of clinical effective cases in control group was 64, accounting for 85.33%, and the total number of clinical effective cases in observation group was 73, accounting for 97.33%. There was a difference in the total clinical effective rate between two groups (P<0.05). Compared with control group after treatment, the number of angina pectoris attacks in observation group was less, the duration of angina pectoris and shortness of breath were shorter, the cardiac output (CO), endothelin (ET), stroke volume (SV), ejection fraction (EF), MCP-1 and soluble vascular intercellular adhesion molecule-1 (sVCAM-1) were lower than those in control group, and ApoA1, nitric oxide (NO) and IGF-1 were higher (P<0.05). The incidence of adverse reactions was 4.00% in control group and 5.33% in observation group (P>0.05). Conclusion: Naoxintong capsules combined with tirofiban in treatment of elderly UAP patients, which can effectively alleviate the clinical symptoms, improve cardiac function, vascular endothelial function and serum ApoA1, IGF-1 and MCP-1 levels. |
